Americans are using more prescription drugs than ever. Consequently, they’re coping with more side effects, drug interactions, and costs, especially if they’re using multiple medications. Kaiser Permanente Washington Health Research Institute (KPWHRI) scientists are on the forefront of answering questions about these concerns. We’re studying the beneficial and harmful effects of medications in real-world settings, and innovating better ways to manage and monitor drug use.
The institute contributes to national initiatives to monitor medication safety as well as providing information to help doctors and patients weigh the risks and benefits of various prescription drugs.
Funders of KPWHRI medication use and patient safety research include the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration, the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and other sources. A few projects include:
Xu S, Newcomer SR, Nelson JC, Chan L, McClure D, Pan Yi, Zeng C, Glanz J. Signal detection of adverse events with imperfect confirmation rates in vaccine safety studies using self-controlled case series design. Biom J. 2014 May;56(3):513-25. doi: 10.1002/bimj.201300012. Epub 2014 Jan 9. PubMed
Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014 Apr;144(2):405-16. doi: 10.1007/s10549-014-2870-5. Epub 2014 Feb 21. PubMed
Ralston JD, Cook AJ, Anderson ML, Catz SL, Fishman PA, Carlson J, Johnson R, Green BB. Home blood pressure monitoring, secure electronic messaging and medication intensification for improving hypertension control: a mediation analysis. Appl Clin Inform. 2014 Mar 12;5(1):232-48. doi: 10.4338/ACI-2013-10-RA-0079. eCollection 2014. PubMed
Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL. Genetic risk factors for major bleeding in warfarin patients in a community setting. Clin Pharmacol Ther. 2014 Jun;95(6):636-43. doi: 10.1038/clpt.2014.26. Epub 2014 Feb 6. PubMed
Turner JA, Saunders K, Shortreed SM, Rapp SE, Thielke S, LeResche L, Riddell KM, Von Korff M. Chronic Opioid Therapy Risk Reduction Initiative: impact on urine drug testing rates and results. J Gen Intern Med. 2014 Feb;29(2):305-11. doi: 10.1007/s11606-013-2651-6. Epub 2013 Oct 19. PubMed
Sascha Dublin, MD, PhDSenior Investigator |
Jessica Chubak, PhDSenior Investigator |
Andrea J. Cook, PhDSenior Biostatistics Investigator |
Rita Mangione-Smith, MD, MPHExecutive Director and Senior Investigator, KPWHRI; Vice President for Research and Health Care Innovation, Kaiser Permanente Washington |
Jennifer C. Nelson, PhDDirector, Biostatistics; Senior Investigator |
David E. Arterburn, MD, MPHSenior Investigator |
Susan M. Shortreed, PhDSenior Biostatistics Investigator |
Lisa A. Jackson, MD, MPHSenior Investigator |
Karen Wernli, PhDSenior Investigator |
Onchee Yu, MSPrincipal Collaborative Biostatistician |
Rod L. Walker, MSPrincipal Collaborative Biostatistician |
Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
Gaia Pocobelli, PhDSenior Collaborative Scientist |
Laura Harrington, PhD, MPHAssistant Investigator |
Jennifer F. Bobb, PhDAssociate Biostatistics Investigator |
Weiwei Zhu, MSSenior Collaborative Biostatistician |
Paige D. Wartko, PhD, MPHSenior Collaborative Scientist |
Maricela Cruz, PhDAssistant Biostatistics Investigator |
Brian D. Williamson, PhDAssistant Biostatistics Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Laurel Hansell, MA, MPHCollaborative Scientist |
Jess Mogk, MPHCollaborative Scientist |
Annie Piccorelli, PhDSenior Collaborative Biostatistician |
Susan Heckbert, MD, PhD
University of Washington (UW) Department of Epidemiology; UW Cardiovascular Health Research Unit
David Siscovick, MD, MPH
UW Department of Medicine; UW Department of Epidemiology; UW Cardiovascular Health Research Unit
Leslie Spangler, PhD
Amgen